Bicyclic Hydroxamic Acid Derivatives for Selective HDAC6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors, particularly those targeting class I isoforms, exhibit significant toxicities and narrow therapeutic windows, limiting their application in treating cancers and other diseases due to their broad-spectrum effects, whereas selective inhibition of HDAC6 offers a potential route to reduce toxicity and expand treatment options for various disorders.
Innovation Solution
Development of novel bicyclic hydroxamic acid derivatives with selectivity for HDAC6, which are designed to inhibit the enzyme's activity while minimizing effects on other HDAC classes, thereby reducing toxicity and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum HDAC inhibitors targeting class I isoforms are used, then HDAC inhibition activity is achieved, but toxicity increases and therapeutic window narrows
Solution Approach 1:
The patent applies local quality by designing hydroxamic acid derivatives with specific molecular structures (Formula I and II) that confer selective affinity for HDAC6 over other HDAC isoforms. The compounds contain specific substituents (R1-R6, R8-R11) and structural features (bicyclic systems, heteroaryl groups) that create localized interaction patterns with the HDAC6 active site, enabling selective inhibition while sparing other HDAC classes, thereby reducing off-target toxicity.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the hydroxamic acid derivatives, including the nature of substituents (R groups), ring systems (saturated vs. unsaturated), and linker lengths (Q1-Q22). These parameter modifications tune the compounds' selectivity profile, optimizing binding affinity for HDAC6 while minimizing interactions with other HDAC isoforms, thus improving the therapeutic window.
2Object-affected harmful factors
If selective HDAC6 inhibition is achieved, then toxicity is reduced, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the HDAC6 inhibitor into distinct functional modules: a hydroxamic acid warhead (for zinc binding), a central bicyclic core structure (for selectivity), and variable substituent groups (R1-R6, R8-R11) that fine-tune affinity and pharmacokinetic properties. This modular segmentation allows systematic optimization of selectivity while maintaining manageable structural complexity.
Solution Approach 2:
The patent employs composite materials by combining different structural elements (heteroaryl rings, cycloalkyl groups, alkylene linkers, hydroxamic acid moieties) into a composite molecular architecture. This composite approach enables the integration of multiple functions (binding, selectivity, pharmacokinetic optimization) within a single molecule, achieving HDAC6 selectivity without excessive complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate selective inhibition of HDAC6, potentially offering a safer and more effective treatment for cancers, autoimmune disorders, mental disorders, and neurodegenerative diseases by reducing toxicity and expanding the therapeutic window compared to traditional HDAC inhibitors.
Implementation Method 1
These compounds are useful as inhibitors of histone deacetylase, and in particular as selective inhibitors of histone deacetylase 6 (HDAC6)
Data Source
AI summary
A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.